8th Jan 2025 11:47
4basebio PLC - Cambridge, England-based life sciences company and manufacturer of synthetic DNA products - Names Gabe Longoria as the new chief commercial officer. Longoria was previously CCO at Astrea Bioseparations Ltd. The appointment follows a GBP40 million investment into 4basebio by Elevate Medical Technologies and M&G Investment Management Ltd, which completed in November. This is a "key milestone" for the company.
Chief Executive Officer Heikki Lanckriet says: "As we focus on capitalising on our recent GBP40 million investment, Gabe's leadership will be invaluable in accelerating our efforts to bring our synthetic DNA products to market and deliver value to our customers and stakeholders."
Current stock price: 1,208.00 pence
12-month change: up 73%
By Emily Parsons, Alliance News reporter
Comments and questions to [email protected]
Copyright 2025 Alliance News Ltd. All Rights Reserved.
Related Shares:
4basebio Plc